Atara Biotherapeutics, Inc. (0HIY.L)
| Previous close | 14.38 |
| Open | 13.28 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 13.28 - 13.28 |
| 52-week range | 13.28 - 13.28 |
| Volume | 10 |
| Avg. volume | N/A |
| Market cap | 1.277B |
| Beta (5Y monthly) | 2.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings date | 01 Mar 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock to 24 newly hired employees and stock options to purchase an aggregate of 82,342 shares of Atara’s common stock to five such newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 1, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Simply Wall St.
We're Hopeful That Atara Biotherapeutics (NASDAQ:ATRA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell transplantation (HCT). The results were featured in an oral presentation at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021), taking place virtually from March 14 - 17, 2021.
